Ahmed M. Amer MD, Abstract Co-Author: Nothing to Disclose

Ginu A. Thomas MBBS, Abstract Co-Author: Nothing to Disclose

Jixin Wang PhD, Abstract Co-Author: Nothing to Disclose

Pascal O. Zinn MD, Abstract Co-Author: Nothing to Disclose

Rivka Rachel Colen MD, Presenter: Nothing to Disclose

To create an imaging genomic biomarker signature in order to identify those Glioblastoma patients (GBM) with 1p/19q deletion. Recent prospective randomized clinical trials have validated correlations between 1p/19q codeletion and increased overall survival of patients treated with radiation therapy with or without chemotherapy

Using The Cancer Genome Atlas (TCGA),we identified 99 treatment naive GBM patients for whom both gene and miRNA expression profiles including the 1p/19q codeletion status, and pretreatment brain MR Imaging from The Cancer Imaging Archive(TCIA) were available. The VASARI feature set and 3D Slicer software 3.6 (http://www.slicer.org) were used for image analysis and image review was done in consensus by 2 neuroradiologists. Fluid Attenuated Inversion Recovery (FLAIR) was used for segmentation of the edema/cellular infiltration and Post GD T1-weighted imaging (T1WI) for segmentation of tumor enhancement  and necrosis. Imaging parameters were then correlated with 1p/19q deletion status and gene expression profiles. Multiple complex biomarker signatures based on gene profiling and survival were created.

A novel imaging biomarker signature using multiple imaging parameters predicted 1p/19q co-deletion in patients with GBM. These were also associated with overall survival and progression-free survival.

Imaging genomic signatures can be expected to promote a more robust personalized approach to patient care and accelerate drug development and help stratify patients in clinical trials. An imaging biomarker signature was created using both qualitative and quantitative imaging parameters that predicted 1p/19 deletion status and expression.

Prediction of 1p/19q status promotes a more effective personalized therapy and help stratify patients in clincial trials

Amer, A, Thomas, G, Wang, J, Zinn, P, Colen, R, Identification of Glioblastoma Radiophenotypes in Patients with 1p/19q Co-deletion.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14011155.html